(a) In order to ensure the public health and safety, an authorized entity that acquires auto-injectable epinephrine shall ensure that:
(1) An expected user:
(A) Completes appropriate knowledge and skills courses at least one (1) time every two (2) years in anaphylaxis and auto-injectable epinephrine use; and
(B) Obtains a certificate under this subchapter;
(2) The auto-injectable epinephrine is maintained according to the manufacturer's operational guidelines and instructions in a locked, secure location; and
(3) A person who renders emergency care or treatment to a person having an anaphylactic reaction by using auto-injectable epinephrine activates the emergency medical services system as soon as possible and immediately reports the use of auto-injectable epinephrine to the medical provider responding to the emergency.
(b) An authorized entity and its expected users may:
(1) Obtain a prescription in the name of the authorized entity for epinephrine auto-injectors and acquire epinephrine auto-injectors under the prescription;
(2) Provide auto-injectable epinephrine for immediate self- administration to an individual who the authorized entity or expected user believes in good faith is experiencing anaphylaxis, regardless of whether the individual has a prescription for auto-injectable epinephrine or has previously been diagnosed with an allergy; and
(3) Administer auto-injectable epinephrine directly to an individual who the authorized entity or expected user believes in good faith is experiencing anaphylaxis, regardless of whether the individual has a prescription for auto-injectable epinephrine or has been previously diagnosed with an allergy.
(c) An authorized entity that possesses and makes available auto-injectable epinephrine shall:
(1) (A) Submit to the Department of Health a report of each incident on the authorized entity's premises in which the authorized entity provides or administers auto-injectable epinephrine.
(B) The department annually shall publish a report that summarizes and analyzes the reports submitted under this subdivision (c)(1); and
(2) Notify an agent of emergency communications, 911, or vehicle dispatch center of the existence, location, and type of auto-injectable epinephrine.
Section: Previous 20-13-402 20-13-403 20-13-404 20-13-405 20-13-406 20-13-407 20-13-408Last modified: November 15, 2016